New York Lung Cancers Symposium | Conferences

Inhibitors of MET, RET, and TRK Now Enjoy Standard of Care Status in Lung Cancer

November 09, 2020

Alexander Drilon, MD, chief of Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, discussed each of the recently approved agents used for the treatment of these tumors and presented a review of the data at the 15th Annual New York Lung Cancer Symposium.

KRAS Now a Druggable Target in Non–Small Cell Lung Cancer

November 09, 2020

As the field of lung cancers continues to lean further into the precision medicine era, KRAS G12C has become an emerging actionable target for which multiple therapies are under development, said Bob T. Li, MD.

COVID-19 Pandemic Creates Teachable Moment for Oncologists in Lung Cancer

November 09, 2020

Many challenges have arisen as a result of the coronavirus 2019 pandemic, which is still impacting nations across the world. In the United States, oncologists have initiated research to provide wider understanding of the virus and the threat it poses to patients with lung cancer.

Importance of Testing Clearer as Research Looks Further Into Targeting Actionable Alterations in Lung Cancer

November 07, 2020

In an interview with Targeted Oncology, Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discussed the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.

TMB Use as Immunotherapy Biomarker Fraught by Challenges, But Still Shows Potential

November 07, 2020

Tumor mutational burden has been correlated with response to immunotherapy use in patients treated with immune checkpoint blockade. However, use of this biomarker has been challenged along the way with various criticisms of validity and routine use.

Immunotherapy Advances Treatment Landscape for Small Cell Lung Cancer

November 07, 2020

An important milestone in the treatment landscape of extensive-stage small cell lung cancer has been trials of first-line chemoimmunotherapy. However, a study that requires better understanding of the methods and can be used to determine patients who are likely to experience durable benefits to therapy is currently concentrated.

Plasma Genotyping May Change Practice in NSCLC, Says Li

November 12, 2019

In a presentation describing the utility of circulating tumor DNA liquid biopsy assays at the 14th Annual New York Lung Cancers Symposium, Bob T. Li, MD, MPH, said that plasma genotyping demsonstrates practice-changing potential in non–small cell lung cancer.